Acamprosate to Reduce Symptoms of Alcohol Withdrawal

• Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00106106
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
• Enrollment: 56
• Location: 1
• Arms: 2
• Duration (Months): 64
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

This study will examine whether a new drug called acamprosate can be helpful for alcohol withdrawal, a result of drinking high amounts of alcohol for long periods of time. Alcohol withdrawal can cause various symptoms, including nausea or vomiting, anxiety or depression, tremor, high blood pressure, and others. During withdrawal, brain chemicals called neurotransmitters change, with some rising to abnormally high levels. These changes may contribute to alcohol craving, drinking relapse and impaired mental performance. This study will see if taking acamprosate for 4 weeks can lower the levels of neurotransmitters, such as glutamate, lessen withdrawal symptoms and decrease alcohol craving and brain damage associated with withdrawal.

Healthy normal volunteers and alcohol-dependent patients between 21 and 65 years of age may be eligible for this study.

Participants are admitted to the hospital for 28 days. They receive standard inpatient care for alcohol detoxification, including a medical history and physical examination, neurological evaluation, laboratory tests, nursing, nutrition, discharge planning and referrals for treatment of concomitant conditions, if needed. In addition, they are randomly assigned to take either two acamprosate or two placebo pills three times a day for 28 days and undergo the following tests and procedures:

• Days 1-28: Drug treatment. Patients take acamprosate or placebo daily. Patients with severe withdrawal symptoms may also receive diazepam (Valium). Throughout their hospitalization, patients fill out questionnaires about their emotional state and personality and are interviewed by staff about their mental health, use of alcohol, cigarettes, and illicit drugs, employment, support systems and family and social relationships, and their legal status.

• Days 2 and 3: Blood tests. Blood is tested for levels of the stress hormones cortisol and ACTH, which are released to excess during alcohol withdrawal. For this test, a heparin lock (thin, flexible plastic tube with a rubber stopper on the end) is placed in an arm vein for blood collections each day at 6 AM, 12 noon, 6 PM and 12 midnight. Patients rest in bed for 30 minutes before each collection.

• Day 4: Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). These procedures are done at the same time. They use a strong magnetic field and radio waves to show structural and chemical changes in the brain. The patient lies on a table in a space enclosed by a metal cylinder (the scanner) for about 20 to 30 minutes during the test.

• Day 5: Lumbar puncture (spinal tap). A local anesthetic is given to numb the area for the procedure. Then, a needle is inserted in the space between the bones in the lower back where the cerebrospinal fluid circulates below the spinal cord. A small amount of fluid is collected through the needle.

• Days 5 and 6: Dexamethasone-corticotropin releasing factor (CRF) test. This test measures the effect of alcohol withdrawal on ACTH and cortisol. The patient takes a standard dose of the steroid dexamethasone at 11 PM on day 5. At noon the next day, they are given lunch and then stay in bed and rest. A plastic tube is put in an arm vein. A salt water solution is slowly infused through the catheter and a blood sample is withdrawn through it. At 3 p.m., the patient is given 100 micrograms of the hormone CRF. Repeated blood samples are obtained to measure ACTH and cortisol.

• Days 23-27: All of the tests done on days 2-6 are repeated, except the MRI. MRS is repeated to measure neurotransmitters.

Condition or Disease	Intervention/Treatment	Phase
Alcohol-Related Disorders; Alcohol Dependence; Alcoholism; Healthy Volunteer	Procedure: NMR-spectroscopy; Drug: Oral acamprosate	Phase 2

Detailed Description

Objective: Clinical as well as preclinical studies indicate that the process of developing alcohol dependence recruits a progressively aggravated hyperglutamatergic state, which in turn is a key signal for emotional dysregulations leading to craving and relapse, as well as neurotoxicity leading to cognitive impairment and loss of grey matter in alcoholic patients. Acamprosate has recently been approved for relapse prevention in sober alcoholics, an effect mediated through largely unknown mechanisms. Preclinical data indicate, however, that it might primarily be useful for targeting the hyperglutamatergic state that develops during recurring withdrawal episodes, halting the process described above. If so, acamprosate might be of value as a withdrawal treatment to prevent the progression of alcohol dependence. The aim of the present protocol is to evaluate, in a randomized controlled trial, the effects of acamprosate during withdrawal and the early post-withdrawal phase. The primary outcome variable will be central glutamate/glutamine concentration as determined by MR spectroscopy. A number of exploratory biological and clinical measures will in addition be obtained and used for secondary analyses as specified below.

Study Population: We will study patients age 21 - 65, without gross impairment of judgment or complicated psychiatric or other morbidity, going into withdrawal or with a high probability of doing so, will be admitted as inpatients to the NIAAA CC-unit. A group of healthy volunteers who do not receive study medication will be examined separately in order to confirm that a hyperglutamatergic state is present in the patients during withdrawal.

Design: All patients will receive standard care for alcohol detoxification. In addition, half of them will be randomized in a blinded fashion to oral acamprosate, two 333 mg tablets taken 3 times daily or corresponding placebo. Validated rating scales (CIWA-Ar, CPRS-SA) will be used to assess intensity of withdrawal and psychopathology. If severity of withdrawal exceeds a predefined criterion, standard diazepam treatment will be added to study medication. The accrual target is based on a primary analysis sample of patients who will not require diazepam medication, which is a potential confound. A secondary analysis will be carried out on the complete sample, analyzing the requirement for/amount of diazepam supplement as a secondary outcome variable.

Outcome Measures: A battery of tests will be obtained during the 1st and 3rd week of inpatient treatment. These will include NMR-spectroscopy to quantify central levels of excitatory and inhibitory amino acids (primary outcome variable: GluX concentration); lumbar puncture to obtain CSF for analysis of neurotransmitter/neurohormone metabolites and synaptic proteins. Repeated 4 x daily blood collection for analysis of serum cortisol and ACTH will be obtained to assess spontaneous activity and circadian variation of the HPA-axis, and the combined dexamethasone - CRH test will be carried out to dynamically probe this system, and gauge its sensitivity for feedback inhibition.

Study Design

• Study Type: Interventional
• Actual Enrollment: 56 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Official Title: Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal
• Study Start Date: Mar 1, 2005
• Actual Primary Completion Date: Jul 1, 2010
• Actual Study Completion Date: Jul 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo For subjects randomized to placebo control, placebo doses were given every 8 hours.	Procedure: NMR-spectroscopy; Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.; Other Names: Magnetic Resonance Spectroscopy MRS
Experimental: Acamprosate For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.	Procedure: NMR-spectroscopy; Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.; Other Names: Magnetic Resonance Spectroscopy MRS ; Drug: Oral acamprosate; For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.; Other Names: Campral

Outcome Measures

Primary Outcome Measures

1. Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 [Day 4]

   The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined.

2. Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25 [Day 25]

   The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 21 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

• INCLUSION CRITERIA - PATIENTS:

1. Alcohol dependence according to DSM-IV, based on the alcohol dependence module of the SCID I-interview, and alcohol withdrawal, based on either of:

Clinically manifest significant alcohol withdrawal symptoms, with or without detectable blood alcohol concentrations.

In absence of the above, current intoxication above 0.1 g/dl BAC, self-reported history of continuous alcohol use > 1 month, and self-reported previous episodes of significantly distressful alcohol withdrawal symptoms, whether treated or not.

1. Age 21 - 65; in younger subjects, maturation processes of the central nervous system are still ongoing; while in older subjects, degenerative changes may confound the measures studied.

2. Smoking status: this will be noted and evaluated using the Fagerstrom inventory, so that its potential contribution to group differences can be assessed. This variable will not otherwise affect inclusion / exclusion.

INCLUSION CRITERIA - HEALTHY CONTROLS:

Subjects will be eligible for inclusion if they are aged 21-65. They will be as closely as possible matched to the patient population with regard to gender and age.

EXCLUSION CRITERIA - PATIENTS:

1. Current or prior history of any disease, including cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders, or a positive hepatitis or HIV test at screening.

2. Current Axis-I psychiatric illness.

3. Current or prior history of any alcohol or drug dependence, as well as non-drinkers (alcohol-naive individuals or current abstainers).

4. Positive result on urine screen for illicit drugs.

5. Nursing, pregnancy or intention to become pregnant for women. Female participants will undergo a urine beta-hCG test to ensure they are not pregnant.

6. Pregnancy (negative test required) or ongoing breastfeeding.

7. Use of prescription or OTC medications know to interact with alcohol within 2 weeks of the study. These include, but may not be limited to: isosorbide, nitroglycerine, benzodiazepines, warfarin, anti-depressants such as amitriptyline, clomipramine and nefazodone, anti-diabetes medications such as glyburide, metformin and tolbutamide, H2-antagonists for heartburn such as cimetidine and ranitidine, muscle relaxants, anti-epileptics including phenytoin and Phenobarbital codeine, and narcotics including darvocet, percocet and hydrocodone. Drugs known to inhibit or induce enzymes that metabolize alcohol should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram. Cough-and-cold preparations which contain anti-histamines, pain medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib and naproxen, should be withheld for at least a 72 hours prior to each study session.

8. Self-reported history of flushing upon intake of alcohol.

9. Inability to undergo an MR scan, due to presence of ferromagnetic objects in their bodies which could cause adverse effects in the MRI scanner, pronounced anxiety provoked by enclosed spaces, or other reasons.

EXCLUSION CRITERIA - HEALTHY CONTROLS:

1. History of any substance use disorder.

2. Average weekly consumption over last 4 weeks, assessed with Time-Line Follow-Back, exceeding 210g pure alcohol / week, or consumption of more than 60g pure alcohol on any single occasion within last 3 days

3. Any history of a psychotic disorder or a history of any other psychiatric diagnosis within the last 12 months

4. Any prescription medication within the last 2 months

5. Pregnant (negative pregnancy test required) or breastfeeding

6. Inability to undergo an MR scan, due to presence of ferromagnetic objects in their bodies which could cause adverse effects in the MRI scanner, pronounced anxiety provoked by enclosed spaces, or other reason

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Institutes of Health Clinical Center (CC)
• National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

• Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S, Yersin B. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med. 2002 May 27;162(10):1117-21.
• Liskow BI, Goodwin DW. Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review. J Stud Alcohol. 1987 Jul;48(4):356-70. Review.
• Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997 Jul 9;278(2):144-51.

• Responsible Party: Markus Heilig, Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• ClinicalTrials.gov Identifier: NCT00106106
• Other Study ID Numbers: 050120; 05-AA-0120
• First Posted: Mar 21, 2005
• Last Update Posted: Jan 12, 2012
• Last Verified: Jan 1, 2012

• Keywords provided by Markus Heilig, Clinical Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA): Alcoholism; Acamprosate; Withdrawal; Glutamate; Magnetic Resonance Spectroscopy; Alcohol Dependence; Healthy Volunteer; HV
• Additional relevant MeSH terms: Alcoholism; Alcohol-Related Disorders; Acamprosate

Study Results

Participant Flow

Arm/Group Title	Placebo	Acamprosate
Arm/Group Description	For subjects randomized to placebo control, placebo doses were given every 8 hours.	For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
Period Title: Overall Study
STARTED	26	23
Completed Both MRS Scans	18	15
COMPLETED	22	19
NOT COMPLETED	4	4

Baseline Characteristics

Arm/Group Title	Placebo	Acamprosate	Total
Arm/Group Description	For subjects randomized to placebo control, placebo doses were given every 8 hours.	For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.	Total of all reporting groups
Overall Participants	26	23	49
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	26 100%	23 100%	49 100%
>=65 years	0 0%	0 0%	0 0%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	35.1 (6.1)	35.0 (5.8)	35.1 (6.5)
Sex: Female, Male (Count of Participants)
Female	11 42.3%	8 34.8%	19 38.8%
Male	15 57.7%	15 65.2%	30 61.2%
Region of Enrollment (participants) [Number]
United States	26 100%	23 100%	49 100%

Outcome Measures

1. Primary Outcome

Title	Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4
Description	The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined.
Time Frame	Day 4

Outcome Measure Data

Analysis Population Description

The analysis of participants was per protocol, i.e., all subjects who completed two MRS scans(Day 4 and Day 25) and for whom there were two measures of the glutamate/creatine ratio

Arm/Group Title	Placebo	Acamprosate
Arm/Group Description	For subjects randomized to placebo control, placebo doses were given every 8 hours.	For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
Measure Participants	18	15
Mean (Standard Error) [Ratio of glutamate to creatine]	1.256772 (0.038924)	1.294178 (0.043249)

2. Primary Outcome

Title	Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25
Description	The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined.
Time Frame	Day 25

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Placebo	Acamprosate
Arm/Group Description	For subjects randomized to placebo control, placebo doses were given every 8 hours.	For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
Measure Participants	18	15
Mean (Standard Error) [Ratio of glutamate to creatine]	1.350375 (0.044497)	1.166667 (0.049441)

Adverse Events

Arm/Group Title	Placebo		Acamprosate
Arm/Group Description	For subjects randomized to placebo control, placebo doses were given every 8 hours.		For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
All Cause Mortality
	Placebo		Acamprosate
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Placebo		Acamprosate
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/26 (0%)		1/23 (4.3%)
General disorders
Vaso-vagal faint	0/26 (0%)	0	1/23 (4.3%)	1
Other (Not Including Serious) Adverse Events
	Placebo		Acamprosate
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	20/22 (90.9%)		18/19 (94.7%)
Gastrointestinal disorders
Diarrhea	3/22 (13.6%)		6/19 (31.6%)
Lack of appetite	3/22 (13.6%)		7/19 (36.8%)
Nausea	2/22 (9.1%)		3/19 (15.8%)
Vomiting	1/22 (4.5%)		2/19 (10.5%)
General disorders
Headaches	7/22 (31.8%)		12/19 (63.2%)
Lack of energy	7/22 (31.8%)		10/19 (52.6%)
Stomach aches	2/22 (9.1%)		8/19 (42.1%)
Musculoskeletal and connective tissue disorders
Muscle spasms	5/22 (22.7%)		3/19 (15.8%)
Nervous system disorders
Abnormal Dreaming	11/22 (50%)		11/19 (57.9%)
Anxiety	9/22 (40.9%)		12/19 (63.2%)
Decreased interest in sex	6/22 (27.3%)		6/19 (31.6%)
Dizziness	5/22 (22.7%)		6/19 (31.6%)
Feeling Down	9/22 (40.9%)		11/19 (57.9%)
Impaired concentration	7/22 (31.8%)		7/19 (36.8%)
Mood swings	9/22 (40.9%)		13/19 (68.4%)
Nervousness	7/22 (31.8%)		10/19 (52.6%)
Sensation of prickling or tingling on the skin	6/22 (27.3%)		2/19 (10.5%)
Shakiness	3/22 (13.6%)		7/19 (36.8%)
Sleepiness	15/22 (68.2%)		13/19 (68.4%)
Sleeplessness	10/22 (45.5%)		12/19 (63.2%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.